Tivic Health CEO Jennifer Ernst to Present at Emerging Growth’s September Virtual Conference

Audio By Carbonatix

FREMONT, Calif.--(BUSINESS WIRE)--Sep 22, 2025--

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that the company’s CEO will present during the Emerging Growth virtual conference set to take place on September 24 & 25, 2025.

Jennifer Ernst, CEO of Tivic, will deliver a formal presentation detailing the company’s strategic transformation into the biopharmaceutical sector. This evolution positions Tivic as a unique innovator addressing disease by integrating both the body’s biochemical and bioelectronic systems.

In February 2025, Tivic secured licensing rights to Statera Biopharma’s TLR5 agonist portfolio, providing the company with a late-stage, highly de-risked drug candidate with a Phase III indication and multiple additional opportunities. At the center of this portfolio is Entolimod, Tivic’s lead commercial opportunity, originally developed as a military countermeasure for exposure to lethal levels of ionizing radiation. Ernst will outline the milestones achieved to date and the significance of these developments as the company advances toward commercialization of Entolimod for the treatment of Acute Radiation Syndrome (ARS).

Ernst will also address Tivic’s second licensed indication, Neutropenia —a condition characterized by low white blood cell counts that compromise the body’s ability to fight infection. Affecting a broad demographic due to causes ranging from genetics to cancer treatments to aging, Neutropenia represents a significant unmet medical need and a substantial market opportunity.

Attendees are encouraged to submit questions in advance for the CEO to address during the presentation. Questions may be emailed to [email protected]. While time is limited, the CEO will make every effort to respond to as many inquiries as possible.

Attendees are welcome to attend and listen to the presentation. Please register for the event at the below link.

https://goto.webcasts.com/starthere.jsp?ei=1717091&tp_key=c78a55764a&sti=tivc

If attendees cannot join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com.

About the Emerging Growth

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Entolimod

Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA’s Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS.

Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia, and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome.

About Tivic Health Systems, Inc.

Tivic’s dual platform utilizes the body’s biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system.

Tivic’s biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company’s lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track and Orphan Drug designations and is in late-stage development.

Tivic’s bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic’s approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: https://ir.tivichealth.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company’s relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company’s future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company’s business strategy; regulatory requirements and pathways for approval; the company’s ability to successfully commercialize its product candidates in the future; the potential opportunities that may be available to the company and its product candidates in the future; the company’s need for, and ability to secure when needed, additional working capital; the company’s ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250922947023/en/

CONTACT: Investor Contact:

Hanover International, Inc.

[email protected] Contact:

Deanne Eagle or Laura Min Jackson

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Tivic Health Systems, Inc.

Copyright Business Wire 2025.

PUB: 09/22/2025 08:30 AM/DISC: 09/22/2025 08:29 AM

http://www.businesswire.com/news/home/20250922947023/en